Mental state and health-related quality of life in patients with polycystic ovary syndrome under metformin therapy – a prospective study.
Saved in:
| Title: | Mental state and health-related quality of life in patients with polycystic ovary syndrome under metformin therapy – a prospective study. |
|---|---|
| Authors: | Hofmann, Konstantin (AUTHOR), Singer, Susanne (AUTHOR), Theis, Susanne (AUTHOR), Dionysopoulou, Anna (AUTHOR), Schiestl, Lina (AUTHOR), Degirmenci, Yaman (AUTHOR), Hasenburg, Annette (AUTHOR), Schwab, Roxana (AUTHOR), Skala, Christine (AUTHOR) |
| Source: | Journal of Psychosomatic Obstetrics & Gynecology. Dec2025, Vol. 46 Issue 1, p1-10. 10p. |
| Subjects: | Polyendocrine metabolic ovarian syndrome, Quality of life, Metabolic disorders, Obesity, Metformin, Insulin resistance, Mental health, Longitudinal method |
| Abstract: | PCOS is one of the most prevalent endocrine disorders among women of reproductive age, often involving obesity, insulin resistance, and mental health challenges that reduce health-related quality of life (HRQOL). Although metformin has been shown to improve HRQOL in PCOS patients, it is unclear whether this effect is due to the drug itself or its metabolic benefits. This study included 66 PCOS patients from the University Medical Center Mainz, in two groups: 31 received metformin (M-group) and 35 received alternative or no treatment (C-group). HRQOL and distress were assessed at baseline and after 6 months using the Modified PCOS-Questionnaire (MPCOSQ) and the Hospital Anxiety and Depression Scale (HADS). At baseline, the M-group had significantly worse metabolic markers, including HOMA-IR, waist circumference, Visceral Adiposity Index, and Fatty Liver Index. By follow-up, this group showed greater improvements in these markers. However, both groups improved similarly in HRQOL and distress. Regression analysis revealed that improvements in HOMA-IR and BMI were associated with better HRQOL scores. Group assignment was not a significant predictor. These findings may indicate that improvements in HRQOL and reduced distress are linked to metabolic changes associated with metformin use, underscoring the potential relevance of addressing metabolic health in treatment approaches. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Psychosomatic Obstetrics & Gynecology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
